Abstract : Highly active antiretroviral therapy is recommended for HIV-infected pregnant women to prevent mother-to-child transmission. The specific physiological background induced by pregnancy leads to significant changes in maternal pharmacokinetics, suggesting potential variability in plasma concentrations of antiretrovirals during gestation. Therapeutic drug monitoring (TDM) of protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) is recommended in certain situations, including pregnancy, but its systematic use in HIV-infected pregnant women remains controversial. This review provides an update of the pharmacokinetic data available for PIs and NNRTIs in pregnant women and highlights the clinical interest of systematic TDM of certain antiretroviral drugs during pregnancy, including nevirapine, nelfinavir, saquinavir, indinavir and lopinavir.
https://www.hal.inserm.fr/inserm-00361996 Contributor : Matthieu RoustitConnect in order to contact the contributor Submitted on : Tuesday, February 17, 2009 - 9:33:14 AM Last modification on : Friday, November 6, 2020 - 4:10:16 AM Long-term archiving on: : Saturday, November 26, 2016 - 5:46:27 AM
File
Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed
until : jamais
Matthieu Roustit, Malik Jlaiel, Pascale Leclercq, Françoise Stanke-Labesque. Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women.. British Journal of Clinical Pharmacology, Wiley, 2008, 66 (2), pp.179-95. ⟨10.1111/j.1365-2125.2008.03220.x⟩. ⟨inserm-00361996⟩